AFA-281 / AfaSci - LARVOL DELTA

A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Afasci Inc

New P1 trial • Addiction (Opioid and Alcohol)

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Afasci Inc

New P2 trial • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Mood Disorders • Pain • Psychiatry • Sleep Disorder

Efficacy Study With AFA-281 for the Treatment of Back Pain (clinicaltrials.gov) - P2 | N=372 | Not yet recruiting | Sponsor: Afasci Inc

New P2 trial • Back Pain • Musculoskeletal Pain • Pain

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=58 | Recruiting | Sponsor: Afasci Inc | Trial completion date: Sep 2024 ➔ Feb 2025 | Trial primary completion date: Aug 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Neuralgia • Pain

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Afasci Inc | Trial completion date: Dec 2024 ➔ Sep 2024 | Trial primary completion date: Oct 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Neuralgia • Pain

Single Ascending Dose and 14-day Study With AFA-281 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Afasci Inc | Not yet recruiting ➔ Recruiting | Initiation date: Jan 2023 ➔ Apr 2023

Enrollment open • Trial initiation date • Neuralgia • Pain

Single Ascending Dose and 14-day Study With AFA-281 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Not yet recruiting | Sponsor: Afasci Inc

New P1 trial • Neuralgia • Pain